297180-15-5
297180-15-5
Chemical Structure
Lipofermata
- CAS No.: 297180-15-5
- Formula:C15H10BrN3OS
- Molecular Weight:360.23
IUPAC Name: 5-bromo-5'-phenyl-3'H-spiro[indoline-3,2'-[1,3,4]thiadiazol]-2-one
InChIKey: RRBYYBWDUNSVAW-UHFFFAOYSA-N
SMILES: O=C1NC2=C(C=C(Br)C=C2)C13SC(C4=CC=CC=C4)=NN3
Biological Activity: Lipofermata is a fatty acid transport protein 2 (FATP2) inhibitor. Lipofermata shows fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. Lipofermata, an analog of spiro-indoline-thadiazole, shows zinc-specific suppression of antibacterial activity. Lipofermata perturbs zinc homeostasis in E. coli K-12 with a MIC of 16 μM[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lipofermata | 99.53% | Lipofermata is a fatty acid transport protein 2 (FATP2) inhibitor. Lipofermata shows fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. Lipofermata, an analog of spiro-indoline-thadiazole, shows zinc-specific suppression of antibacterial activity. Lipofermata perturbs zinc homeostasis in E. coli K-12 with a MIC of 16 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sandoval A, et al. Identification and characterization of small compound inhibitors of human FATP2 [published correction appears in Biochem Pharmacol. 2012 Aug 15;84(4):580]. Biochem Pharmacol. 2010;79(7):990-999. [Content Brief]
- [2]. Ahowesso C, Black PN, Saini N, et al. Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death. Biochem Pharmacol. 2015;98(1):167-181. [Content Brief]
- [3]. Falconer SB, et al. Zinc Chelation by a Small-Molecule Adjuvant Potentiates Meropenem Activity in Vivo against NDM-1-Producing Klebsiella pneumoniae. ACS Infect Dis. 2015;1(11):533-543. [Content Brief]
